Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan
This study will characterize the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of AUY922 in adult patients with advanced solid malignancies in Japan.
Advanced Solid Tumors
DRUG: AUY922
establish maximum tolerate dose (safety and tolerability), about 3 years
Safety assessed by type, frequency and severity of adverse events, about 4 years|Efficacy assessed by RECIST, about 4 years|Pharmacokinetic assessed by Cmax, Tmax, AUC, about 3 years|Pharmacodynamic assessed by blood and tumor biomarkers at baseline and post AUY922, about 4 years
This study will characterize the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of AUY922 in adult patients with advanced solid malignancies in Japan.